Literature DB >> 10715537

A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects.

B Térouanne1, B Tahiri, V Georget, C Belon, N Poujol, C Avances, F Orio, P Balaguer, C Sultan.   

Abstract

We developed a new stable prostatic cell line expressing the human androgen receptor (AR) and the AR-responsive reporter gene to generate a powerful tool for investigating androgen action and for rapid screening of agonists and antagonists. The AR-deficient PC-3 cells were stably transfected with pSG(5)-puro-hAR and pMMTV-neo-Luc. After selection with puromycin and neomycin, one highly inducible clone was isolated and named PALM, for PC-3-Androgen receptor-Luciferase-MMTV. The expression of hAR was confirmed by western blot and steroid-binding assays on the whole cells. The transcriptional activity of the clone was measured after incubation of cells with increasing concentrations of synthetic R1881 or natural androgens (DHT and testosterone). The three agonists had the same maximal activity at 0.1 microM and the fold induction was equal to 20. The agonist and antagonist activities of the steroidal antiandrogens (cyproterone acetate and RU2956) and the non-steroidal antiandrogens (nilutamide, bicalutamide, inocoterone and hydroxyflutamide) measured with the PALM cells were in good correlation with the results obtained with transiently transfected cells. The selectivity in steroid transactivation was demonstrated with estradiol, progesterone, cortisol, dexamethasone and aldosterone. Spironolactone and RU486 showed partial agonist and antagonist activities, whereas R5020 presented only a partial antagonist activity. We here demonstrate that this stable transfectant provides an accurate tool for studying wild-type human AR activation and its regulation by androgens and antiandrogens in a human prostatic epithelial cell, which is routinely available and remains androgen-responsive in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715537     DOI: 10.1016/s0303-7207(99)00251-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

Review 1.  Cell-based assays for screening androgen receptor ligands.

Authors:  Carmela Campana; Vincenzo Pezzi; William E Rainey
Journal:  Semin Reprod Med       Date:  2015-06-02       Impact factor: 1.303

Review 2.  The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.

Authors:  Amy B Cadwallader; Carol S Lim; Douglas E Rollins; Francesco Botrè
Journal:  J Anal Toxicol       Date:  2011-11       Impact factor: 3.367

3.  Androgen-dependent regulation of human MUC1 mucin expression.

Authors:  Stephen Mitchell; Paul Abel; Sanjeev Madaan; James Jeffs; Khurram Chaudhary; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

4.  A multifunctional androgen receptor screening assay using the high-throughput Hypercyt flow cytometry system.

Authors:  Megan K Dennis; Harmony J C Bowles; Debra A MacKenzie; Scott W Burchiel; Bruce S Edwards; Larry A Sklar; Eric R Prossnitz; Todd A Thompson
Journal:  Cytometry A       Date:  2008-05       Impact factor: 4.355

5.  Development of a novel cell based androgen screening model.

Authors:  Carmela Campana; Juilee Rege; Adina F Turcu; Vincenzo Pezzi; Celso E Gomez-Sanchez; Diane M Robins; William E Rainey
Journal:  J Steroid Biochem Mol Biol       Date:  2015-11-12       Impact factor: 4.292

6.  Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity.

Authors:  Iveta Bartonkova; Aneta Novotna; Zdenek Dvorak
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 7.  Reporter Cell Lines for the Characterization of the Interactions between Human Nuclear Receptors and Endocrine Disruptors.

Authors:  Marina Grimaldi; Abdelhay Boulahtouf; Vanessa Delfosse; Erwan Thouennon; William Bourguet; Patrick Balaguer
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-11       Impact factor: 5.555

8.  Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.

Authors:  Isla S Mackenzie; Steven V Morant; Li Wei; Alastair M Thompson; Thomas M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2016-11-12       Impact factor: 4.335

Review 9.  The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.

Authors:  José A Carlos-Escalante; Marcela de Jesús-Sánchez; Alejandro Rivas-Castro; Pavel S Pichardo-Rojas; Claudia Arce; Talia Wegman-Ostrosky
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

10.  Interlaboratory comparison of four in vitro assays for assessing androgenic and antiandrogenic activity of environmental chemicals.

Authors:  Wolfgang Körner; Anne Marie Vinggaard; Béatrice Térouanne; Risheng Ma; Carise Wieloch; Margret Schlumpf; Charles Sultan; Ana M Soto
Journal:  Environ Health Perspect       Date:  2004-05       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.